Vaxcyte, Inc. Stock 12-Month Price Target Adjusted by Analysts
Analysts have slightly lowered the average 12-month price target for Vaxcyte, Inc. to $116.50, while maintaining a consensus “Buy” rating.
Filings · News reference
T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G/A regarding its ownership stake in Vaxcyte, Inc.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analysts have slightly lowered the average 12-month price target for Vaxcyte, Inc. to $116.50, while maintaining a consensus “Buy” rating.
Vaxcyte, Inc. announced its financial results for the third quarter ended September 30, 2026, and provided a business update.
Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
Filed: 2026-10-09 AccNo: 0001193125-26-419174 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.